A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART

TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm(3) and undetectable v...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez, Carmen Elena, Perdiguero, Beatriz, García-Arriaza, Juan, Cepeda, Victoria, Sánchez-Sorzano, Carlos Óscar, Mothe, Beatriz, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Gatell, Jose M., López Bernaldo de Quirós, Juan Carlos, Brander, Christian, García, Felipe, Esteban, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636254/
https://www.ncbi.nlm.nih.gov/pubmed/26544853
http://dx.doi.org/10.1371/journal.pone.0141456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636254/
https://www.ncbi.nlm.nih.gov/pubmed/26544853
http://dx.doi.org/10.1371/journal.pone.0141456

Ejemplares similares